28.8 C
Vientiane
Thursday, August 21, 2025
spot_img
Home Blog Page 22

Compass Mining Deepens Vertical Integration with New 10 MW Site in Partnership with ONMINE

New partnership combines enterprise hosting, shared revenue, power‑pricing risk sharing, and Compass Mining-led operations under one model

WILMINGTON, Del., Aug. 19, 2025 /PRNewswire/ — Compass Mining, a leading provider of Bitcoin mining infrastructure and services, today announces the full energization of a 10 megawatt (MW) facility in Texas, developed in partnership with Onmine. The project demonstrates Compass Mining’s progress toward full vertical integration by placing the company in control of day-to-day operations, sharing revenue with the site owner, and assuming part of the power-pricing risk.

The facility was energized in stages, reaching its full capacity by the end of July. Compass Mining has deployed its own machines to validate performance and streamline the onboarding process for its customers. The company expects to transition the entire 10 MW to hosting for its enterprise clients no later than October 2025.

“This partnership reflects Compass Mining’s evolution from a hosting marketplace into a full-stack mining infrastructure operator,” said Karoon Mackenchery, Director of Hosting Services at Compass Mining. “It’s the first site where we’re not only taking on the day-to-day operations, but also the power pricing risk and revenue responsibility from first self-mining and then customer hosting. Our ability to step into this role is a direct result of the trust we’ve built with enterprise clients and our success in delivering performance at scale.”

“This project demonstrates how Compass Mining’s operational expertise aligns with Onmine’s proven track record in developing scalable, grid-connected infrastructure to serve datacenters,” said Ziyad Elgamal, Co-CEO of Onmine. “By securing the site, fast-tracking interconnection, and integrating Giga’s advanced air-cooled container product line, we brought 10 MW of sustainable capacity online in record time — the first of several Onmine projects energizing this year.”

Compass Mining oversees both onsite and remote operations, while Giga Energy, a leading manufacturer of electrical infrastructure, provides air-cooled modular data centers, which shorten deployment timelines and enhance scalability. Onmine provided the site, secured interconnection with ERCOT, and assisted throughout construction to ensure seamless integration with Compass Mining’s operational requirements. The arrangement allows Compass Mining to offer institutional clients a turnkey hosting solution that includes power contract management, advanced monitoring, and uptime service level agreements, all at competitive rates within ERCOT.

This announcement follows recent expansions in Iowa and West Texas and illustrates Compass Mining’s strategy to build a nationwide network of enterprise‑grade facilities serving both individual miners and large institutional clients.

For more information about Compass Mining, visit www.compassmining.io.

About Compass Mining

Compass Mining is a customer-first company that provides a platform for individuals and businesses to purchase Bitcoin mining hardware, host machines, build and manage mining facilities, and access a range of ancillary services. With a commitment to exceptional customer support and transparency, Compass Mining sets the benchmark for Bitcoin mining hosting. Its mission is to make Bitcoin mining accessible to everyone. To learn more about Compass Mining or to start mining today, visit compassmining.io.

About ONMINE

Onmine is a developer and operator of high-performance energy and data-center infrastructure, delivering scalable solutions for Bitcoin mining, AI/HPC workloads, and other grid-optimization projects. Guided by a vision to eliminate wasted kilowatts through smarter energy usage and storage, Onmine builds infrastructure that accelerates timelines, reduces costs, and drives a more sustainable digital future. With a growing portfolio across Texas and North America, Onmine builds reliable, future-ready energy solutions at scale. Learn more at www.onmine.io.

About Giga Energy

Giga Energy designs and manufactures modular, containerised data-centre and power-distribution systems for high-density computing and industrial applications. Its turnkey infrastructure integrates switchgear, cooling and remote monitoring to enable rapid deployment, reliable performance and flexible scaling. Learn more at www.gigaenergy.com.

Media Contact

BlocksBridge Consulting
compass@blocksbridge.com

Hefei high-tech zone witnesses thriving ecology, innovation

BEIJING, Aug. 19, 2025 /PRNewswire/ — A news from China.org.cn:

As dusk falls, lights illuminate the National Quantum Laboratory along Shuxi Lake’s southern shore, while neighboring commercial complexes glow against the twilight. Researchers jog by the water or debate ideas in cafés. This daily tableau of “people-city-industry” integration epitomizes life in the Hefei National High-tech Industry Development Zone’s “One Mountain, Two Lakes” area.

Hefei National High-tech Industry Development Zone is located in Hefei, capital city of East China's Anhui province.
Hefei National High-tech Industry Development Zone is located in Hefei, capital city of East China’s Anhui province.

Ecological environment: from “green lung” to growth engine

Centered on Dashu Mountain, Shuxi Lake, and Baiyan Lake, the zone forms the core area of high-quality development. With over 95% forest coverage, Dashu Mountain functions as the zone’s “ecological lung,” conserving more than 10 million cubic meters of water annually. 

Shuxi Lake hosts national strategic assets such as the Quantum Lab and Institute of Advanced Technology of the University of Science and Technology of China, surrounded by over 700 high-tech enterprises within a 3-kilometer radius, with 25 firms per square kilometer. Baiyan Lake anchors a soil-water conservation theme park, encircled by premium housing, commerce, and education hubs forging modern ecosystems for living and working.

Innovation highland: global talent convergence

Leveraging this natural advantage, the zone is expanding human-centric development.

In urban development, the zone is implementing systematic improvements across ecology, transportation, education, healthcare, and governance, aligning with the goal of building an innovative, livable, beautiful, resilient, culturally vibrant, and smart modern district. 

Today, premium educational resources span all six areas, prestigious institutions have taken root, medical facilities have been upgraded, and smart lakeside running tracks embody human-centric design, improving living conditions across the board.

Now, around the “One Mountain, Two Lakes,” quantum computing teams are pushing boundaries in core technologies. Grand Union of Innovation incubator gives birth to a tech company every three days. China Speech Valley registers new AI patent filings daily. Scenes of academics and CEOs brainstorming tech commercialization in lakeside cafés now symbolize its vibrant pulse.

Future blueprint: a global model of integrated living

Pursuing a “world-class high-tech zone” status, the zone accelerates the “One Mountain, Two Lakes” vision. At the Zhong’anChuanggu Technology Park, young talents gather at workspaces offering free accommodation and entrepreneurship consultation, chasing dreams amid a beautiful landscapes and supportive business environment.

The Hefei National High-tech Industry Development Zone is leveraging its “One Mountain, Two Lakes” ecological asset as a competitive edge to create a thriving hub for science, industry and a dream place to live.

Hefei high-tech zone witnesses thriving ecology, innovation
http://www.china.org.cn/hefeihightech/2025-08/14/content_118027351.html 

Mint Announces $150 Million Investment Commitment and Initial Exchange Offering

BETHESDA, Md., Aug. 19, 2025 /PRNewswire/ — Green Minting Technologies, Corp. (“Mint”), announced today the strategic investment commitment of up to $150 Million USD with GEM Digital Limited through a token subscription agreement to develop a state-of-the-art, 600-Megawatt, off-grid, renewable energy, Bitcoin mining and AI datacenter project.  The partnership is set to accelerate Mint’s mission of bringing renewably-powered cloud computing to the masses through its $MINT token, which enables tokenholders to buy compute power by the hash in order to leverage low-cost, renewable energy to power applications like Bitcoin mining on Application-Specific Integrated Circuits (“ASICs”) or training Artificial Intelligence (“AI”) on Graphics Processing Units (“GPUs”).  

As part of the $150 Million USD investment commitment, Mint will be listing its $MINT tokens on a number of the leading centralized exchanges in its Initial Exchange Offering (“IEO”), where it is targeting to raise $400 Million USD.  

“Mint is re-democratizing the Bitcoin mining landscape by fractionalizing the energy and computing infrastructure into $MINT Tokens.  In the beginning, Bitcoin mining was truly distributed across individual users. As Bitcoin mining infrastructure becomes increasingly expensive, individual users can’t compete, particularly at today’s retail energy prices.  Through this partnership with GEM, we can deploy our $MINT Tokens to enable individual users to gain the benefit of renewable, scaled operations – without the upfront costs associated with developing utility-scale energy generation and datacenter infrastructure. Bitcoin mining can now be powered by the masses once again, thanks to the $MINT Token,” said Alex Wey, CEO and co-founder.

As part of the 600-Megawatt project, Mint will dedicate a portion of the infrastructure to developing a Tier III/IV datacenter to host GPUs and power AI tools, alongside its core Bitcoin Mining operations. 

To learn more about $MINT, the project, and about how to participate in this Initial Exchange Offering and its Presale, visit the $MINT website https://www.green-mint.com/.

About GEM Digital Limited
Based in the Bahamas, GEM Digital Limited is an asset investment firm focused on utility tokens. Its parent company, Global Emerging Markets (“GEM”), is a $3.4 Billion alternative investment group with offices in Paris, New York, and the Bahamas, spanning asset classes like Small-Mid Cap Buyouts, Private Investments in Public Equities (PIPEs), and select venture investments.

About Mint 

Green Minting Technologies, Corp. (“Mint”), a Delaware corporation, is a renewable energy developer focused on deploying wind and solar power generation to enable its own on-site, off-grid cloud computing infrastructure that powers applications such as bitcoin mining, AI / ML, and HPC.  By deploying its own energy generation infrastructure off-grid, Mint moves some of the most energy-intensive commercial applications away from the residential grid, while simultaneously developing future-proof, carbon-neutral cloud infrastructure for a sustainable cloud computing future. 

Press Inquiries:

press@green-mint.com

(202) 573-9286

 

Doosan Robotics Opens Authorized Training Center at the University of Maine

ORONO, Maine and PLANO, Texas, Aug. 19, 2025 /PRNewswire/ — Doosan Robotics, a global leader in robotics innovation, announced the opening of an Authorized Training Center at the University of Maine’s Advanced Manufacturing Center (AMC) in Orono.  The new facility, housed in AMC’s state-of-the-art B.O.T. Loft, is a dedicated space for robotics, automation, and networked systems training.

Hyunsoo Kim, vice president of sales at Doosan Robotics and Bradley Denholm, Associate Director of Workforce Development at the University of Maine Advanced Manufacturing Center(from left)
Hyunsoo Kim, vice president of sales at Doosan Robotics and Bradley Denholm, Associate Director of Workforce Development at the University of Maine Advanced Manufacturing Center(from left)

The training center will provide hands-on instruction in robot programming, system integration, and industrial applications using Doosan Robotics’ systems, along with a variety of other robotic technologies. The curriculum is designed to serve both students and the general public, offering accessible, skill-based education aligned with the needs of today’s high-tech workforce. Doosan Robotics will support the center with official training materials, structured lesson plans, and educational robot kits.

Located in the heart of the AMC, the B.O.T. Loft is a hub for workforce development in Maine and beyond. It offers training opportunities ranging from K–12 summer programs to professional certifications. Doosan’s involvement expands the diversity of technology offered within the space and reinforces the university’s mission to deliver industry-aligned, real-world training opportunities.

This partnership also marks the expansion of Doosan Robotics’ U.S. training network, joining its existing Authorized Training Center in Plano, Texas. Through this collaboration, Doosan aims to contribute to the development of a highly skilled robotics workforce while supporting the broader adoption of intelligent automation.

“Establishing a robust education ecosystem is just as important as developing advanced robot technology,” said Hyunsoo Kim, vice president of sales at Doosan Robotics. “By expanding our network of training centers and continuously enhancing our curriculum, we aim to nurture the next generation of robotics experts and drive broader adoption of intelligent robots worldwide.”

“We’re thrilled to expand our relationship with Doosan Robotics and to host the company’s first university-based Authorized Training Facility in North America,” said John Belding, director of the Advanced Manufacturing Center at the University of Maine. “Partnering with a global leader like Doosan allows UMaine to offer direct, hands-on experience with the advanced technology that is shaping the future of manufacturing, and this relationship exemplifies our commitment to regional workforce development in the high-demand fields of robotics and automation.”

This initiative also benefits from the presence of Industrial Automation Supply, Doosan Robotics’ authorized distributor in Portland, Maine, which provides regional manufacturers with access to automation and robotics solutions.

The University of Maine, founded in 1865, is the state’s only public research university and a recognized leader in advanced manufacturing education. The AMC B.O.T. Loft exemplifies the university’s commitment to hands-on, experiential learning in robotics and automation, serving students, educators, and industry professionals alike.

About Doosan Robotics
Doosan Robotics, founded in 2015 and a subsidiary of the Doosan Group (est. 1896), designs and manufactures high-performance robotic systems that drive automation in manufacturing, packaging, logistics, healthcare, research, and more. In 2022, the company established its U.S. headquarters in Plano, Texas. Doosan Robotics is known for its user-friendly, adaptable, and reliable robot systems. With a global presence spanning multiple vertical industries, Doosan Robotics continues to support innovation and operational excellence worldwide. More information is available at www.doosanrobotics.com.

About the University of Maine: As Maine’s only public research university and a Carnegie R1 top-tier research institution, the University of Maine advances learning and discovery through excellence and innovation. Founded in 1865 in Orono, UMaine is the state’s land, sea and space grant university with a regional campus at the University of Maine at Machias. Our students come from all over the world and work with faculty conducting fieldwork around the globe — from the North Atlantic to the Antarctic. Located on Marsh Island in the homeland of the Penobscot Nation with UMaine Machias located in the homeland of the Passamaquoddy Nation, UMaine’s statewide mission is to foster an environment that creates tomorrow’s leaders. As the state’s flagship institution, UMaine offers nearly 200 degree programs through which students can earn bachelor’s, master’s, professional master’s and doctoral degrees as well as graduate certificates. For more information about UMaine and UMaine Machias, visit umaine.edu/about/quick-facts/ and machias.edu/about-umm/umm-facts/.      

Media Contact
Stephanie Callaway
Marketing Director
Doosan Robotics Americas
Phone: 469-885-5644
Email: stephanie.callaway@doosan.com 

Doosan Robotics Opens Authorized Training Center at the University of Maine
Doosan Robotics Opens Authorized Training Center at the University of Maine

LambdaTest Unveils the World’s First Platform to Test AI Agents: Introducing Agent-to-Agent Testing

AI-native Multi-Agent System Delivers Smarter, Faster, and More Comprehensive Software Testing

SAN FRANCISCO, Aug. 19, 2025 /PRNewswire/ — LambdaTest, the leading AI-native testing platform, has launched the private beta release of its Agent-to-Agent Testing, the world’s first platform designed to validate and assess AI agents. With the rise of AI agents in developer workflows, the platform is set to revolutionize the way organizations test and validate their AI agents across conversation flows, intent recognition, tone consistency, complex reasoning, and beyond.

As enterprises increasingly rely on AI agents to power customer experiences, a critical challenge has emerged: no standard way of testing various AI Agents. These agents interact with users and systems in ways that are dynamic and unpredictable, making it hard to ensure their reliability and performance. Traditional testing methods fall short when the system under test is inherently unpredictable.

Organizations need a new, smarter way to test AI applications at scale, which is where Agent-to-Agent Testing comes in. LambdaTest’s Agent-to-Agent Testing platform is the first of its kind. The platform uses a suite of specialized AI testing agents to rigorously validate chat and voice AI agents..

Teams can upload existing requirement documents in various formats, such as text, images, audio, and video, and the system automatically handles multi-modal analysis to generate relevant test scenarios, simulating real-world challenges that could break the AI agent under test. Each scenario includes precise validation criteria and expected responses, evaluated within HyperExecute, LambdaTest’s next-gen test orchestration cloud, delivering up to 70% faster test execution than standard automation grids.

The platform highlights different key metrics like Bias, Completeness, Hallucinations, etc., to help teams analyse the quality of their AI agent

By integrating agentic AI and GenAI technologies, it generates real-world scenarios such as tone of personality agents, data privacy considerations, and executes test cases with unparalleled accuracy. This ensures much broader and more diverse test coverage compared to traditional testing tools. Unlike single-agent systems, LambdaTest’s Agent-to-Agent Testing leverages multiple large language models (LLMs), which the agents use for reasoning and test generation. This multi-agent approach results in a much more comprehensive and detailed test suite, enabling deeper, more robust testing of AI applications.

“Every AI agent you deploy is unique, and that’s both its greatest strength and its biggest risk! As AI applications become more complex, traditional testing approaches simply can’t keep up with the dynamic nature of AI agents,” said Asad Khan, CEO and Co-Founder at LambdaTest. ” Our Agent-to-Agent Testing platform thinks like a real user, generating smart, context-aware test scenarios that mimic real-world situations your AI might struggle with. Each test comes with clear validation checkpoints and the responses we’d expect to see.”

Enterprises using Agent-to-Agent Testing will experience faster test creation, evaluation of Agents, reduced testing cycles, and significant improvements in test coverage. The multi-agent system can generate a 5 to 10-fold increase in test coverage, providing a more comprehensive view of AI agent performance.

Furthermore, the integration with HyperExecute means teams receive rapid feedback, reducing the time between testing and iteration. By automating much of the testing process, companies also reduce their reliance on manual QA efforts, resulting in significant cost savings. With 15 purpose-built AI testing agents ranging from security researchers to compliance validators, LambdaTest Agent-to-Agent testing ensures every deployment is as robust, safe, and reliable as possible. Helping teams ship their AI agents with confidence.

Learn more about Agent-to-Agent Testing by LambdaTest here: https://www.lambdatest.com/agent-to-agent-testing

To watch the live unveiling of the platform, join the Testμ Conference 2025 on 20th August, 2025: https://www.lambdatest.com/testmuconf-2025

About LambdaTest

LambdaTest is a GenAI-powered Quality Engineering Platform that empowers teams to test intelligently, smarter, and ship faster. Built for scale, it offers a full-stack testing cloud with 10K+ real devices and 3,000+ browsers.

With AI-native test management, MCP servers, and agent-based automation, LambdaTest supports Selenium, Appium, Playwright, and all major frameworks. AI Agents like HyperExecute and KaneAI bring the power of AI and cloud into your software testing workflow, enabling seamless automation testing with 120+ integrations.

LambdaTest Agents accelerate your testing throughout the entire SDLC, from test planning and authoring to automation, infrastructure, execution, RCA, and reporting.

For more information, please visit https://lambdatest.com

 

 

NYSE Content Advisory: Pre-Market Update + Retail Earnings Kick Off

NEW YORK, Aug. 19, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

NYSE Content Advisory: Pre-Market Update + Retail Earnings Kick Off

Ashley Mastronardi delivers the pre-market update on August 19th

  • Stocks are mixed after Monday saw little change to the major averages. The retail sector will make headlines today as NYSE-listed Home Depot released earnings ahead of market open.
  • Investors will be keeping a close eye on the numbers to gauge how the consumer is faring amid inflation and trade policy uncertainty.
  • Investors are bracing for what the Fed says later this week at its annual Economic Policy Symposium at Jackson Hole, Wyoming. Chair Powell will deliver his remarks on Friday.

Opening Bell
EB Research Partnership celebrates three FDA-approved treatments for EB in the pursuit of a cure

Closing Bell
Action Against Hunger honors our 8,900+ staff worldwide

Click here to download the NYSE TV App

Video – https://mma.prnasia.com/media2/2753599/NYSE_Market_Update_Aug_19.mp4

 

WuXi Biologics Reports Solid 2025 Interim Results

  • Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2%
  • IFRS Gross profit margin expanded by 3.6% YoY to 42.7%
  • EBITDA grew 50.5% YoY and IFRS net profit increased 54.8% YoY
  • Adjusted EBITDA grew 20.6% YoY and adjusted net profit increased 11.6% YoY
  • FY25 group revenue growth target raised to 14% – 16%
  • A first-half record of 86 new integrated projects added, including 2 in late-stage
  • Total integrated projects reached 864, one of the largest portfolios of complex biologics
  • Late-stage and CMO revenue rose 24.9% YoY; 25 PPQs scheduled for 2025
  • Total backlog increased to US$20.34 billion; backlog within 3 years increased to US$4.21 billion
  • Optimized global operations and enhanced capacities to support sustainable growth

HONG KONG, Aug. 19, 2025 /PRNewswire/ — WuXi Biologics (Cayman) Inc. (“WuXi Biologics” or “the Group”, stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the first half of 2025 (“Reporting Period”).

Financial Highlights

Revenue: The Group’s revenue for the Reporting Period increased by 16.1% YoY to RMB9,953.2 million. The growth was primarily driven by: (i) the continued success of the Group’s “Follow and Win the Molecule” strategies, supported by its leading technology platforms, best-in-industry timelines and strong execution record; (ii) an expanded range of services offered across the biologics value chain – including discovery, pre-IND development, and clinical and commercial manufacturing – with notable momentum in fast-growing platforms such as antibody-drug conjugates (ADCs), and bi- & multi-specific antibodies; (iii) growth in research services revenue, underpinned by the Group’s cutting-edge technologies; and (iv) increased utilization of both existing and newly expanded capacity, including the ramp-up of the Group’s manufacturing facility in Europe.

Gross Profit and Gross Profit Margin: IFRS gross profit increased 27.0% YoY to RMB4,252.9 million, while adjusted gross profit rose 19.2% YoY to RMB4,543.4 million. IFRS gross profit margin reached 42.7%, with adjusted gross profit margin at 45.6%. The improvement in gross profit margin was primarily driven by favorable volume and mix, enhanced efficiency and process optimization achieved through the Group’s WBS and digitalization initiatives.

EBITDA and EBITDA Margin: EBITDA grew 50.5% to RMB4,221.8 million, while adjusted EBITDA increased 20.6% YoY to RMB4,305.2 million. EBITDA margin reached 42.4%, and adjusted EBITDA margin expanded to 43.3%.

Net Profit and Net Profit Attributable to Owners of the Company: IFRS net profit rose 54.8% YoY to RMB2,756.6 million, while net profit attributable to owners of the Company grew 56.0% to RMB2,339.3 million. This growth was primarily driven by higher gross profit, the gains from the Group’s investment and asset divestiture activities.

Adjusted Net Profit: Adjusted Net Profit for the period increased 11.6% YoY to RMB2,840.0 million, with an adjusted net profit margin of 28.5%.

Basic Earnings Per Share (EPS): Basic EPS rose 56.8% from RMB 0.37 for the six months ended June 30, 2024 to RMB 0.58 for the six months ended June 30, 2025. Diluted EPS increased by 57.1% from RMB 0.35 to RMB 0.55 over the same period.

Business Highlights

  • Integrated Project Wins

The Group added 86 integrated projects in the first half of 2025, bringing the total to 864. Over half of these new projects were originated from U.S. clients, reflecting continued client trust and the resilience of the Group’s CRDMO business model amid ongoing market volatility. The Group supports 67 late-stage and 24 commercial projects, establishing a strong foundation for sustained future manufacturing revenue growth.

Of the 86 new projects, 9 were post-IND wins under the Group’s “Win-the-Molecule” strategy, including 2 in late-stage. Most of these involve complex modalities such as bi- and multi-specific antibodies, and ADCs.

  • Research

Building on its industry-leading technology platforms and growing global recognition, the Group’s Research business maintained strong momentum in the first half of 2025. Ongoing partnerships with global innovators continued to advance discovery programs across bi- and multi-specific TCEs and ADCs. These collaborations reflect strong client trust and further expand the Group’s biologics pipeline. Notably, a molecule developed for GSK recently entered clinical trials, becoming the fourth WuXi Biologics–originated TCE to reach the clinic stage. To date, the Group’s Research Services has enabled 50+ programs that are potentially eligible for future milestone payments and sales royalties, unlocking significant upside for the Group’s long-term profitable growth.

  • Development

The Group added a first-half record of 86 new integrated development projects in the first half of 2025, further expanding one of the industry’s largest portfolios of complex biologics. Bi- & multi-specifics, along with ADCs, accounted for over 70% of new signs, expanding our portfolio to 168 bi- & multispecifics, 225 ADCs, 80 fusion proteins, 25 vaccines and 326 mAbs – highlighting the Group’s strong execution and leadership in next-generation modalities.

During the Reporting Period, the Group’s pre-IND revenue rose 35.2% YoY, driven by revenue conversion of wins across Research services and pre-IND development. Supported by the Group’s proprietary cell line development platform WuXiaTM, over 600 projects with potential cell line royalty are expected by the end of 2025. Amid continued momentum in innovative drug out-licensing from China, the Group remained a critical partner in global biopharma discovery and development collaborations, supported by its industry-leading technology platforms and operational excellence.

During the Reporting Period, the Group launched WuXiHigh™2.0, its next-generation high-throughput formulation platform for high concentration biologics. By leveraging proprietary excipient blends and formulation expertise, the platform enables protein concentrations of up to 230 mg/mL and reduces viscosity by up to 90% – while preserving stability and injectability. This innovative platform reflects the Group’s ongoing commitment to technological advancement and empowers clients to accelerate development and enhance patient delivery.

  • Manufacturing

As of June 30, 2025, the Group has supported 67 late-stage projects and 24 commercial manufacturing projects, and remains on track to complete 25 scheduled process performance qualification (PPQ) campaigns in 2025. During the Reporting Period, late-phase and commercial manufacturing revenue increased by 24.9% YoY, reflecting both evolution of projects from early-phases and the continued ramp-up of existing CMO programs. To meet the growing commercial demands and ensure supply chain reliability, the Group continues to implement its “Global Dual Sourcing” strategy by expanding capacity and capabilities across its global manufacturing network:

    • Ireland: MFG6.2 successfully released three 1,000L single-use bioreactor systems, increasing total perfusion capacity from 3,000L to 6,000L. The first engineering and PPQ runs were both successfully completed during the Reporting Period. Meanwhile, MFG7 completed its second 12,000L PPQ run. In addition, MFG6 recently received its first EMA approval as a commercial manufacturing site for a global client’s innovative biologic, underscoring the consistency and strength of WuXi Biologics’ quality systems. To date, the Ireland site has maintained a 100% success rate for all PPQ runs.
    • Singapore: Construction has begun on a new modular drug product (DP) facility, while design work is underway for a planned drug substance (DS) modular facility within the CRDMO hub. Additionally, mechanical completion was achieved at the XDC manufacturing site. Operations are expected to commence by the end of 2025, with GMP manufacturing to follow in early 2026. The Group is making solid strides according to the planned schedule to establish Singapore as another strategic hub for our global biologics Research, Development and Manufacturing services.
    • U.S: Construction at MFG11 (Worcester, MA) is advancing, with the facility designed to house six 6,000L single-use bioreactors connected to a single downstream line, enabling high-throughput processing and advanced automation. Once operational, MFG11 will be seamlessly integrated with MFG18 (Cranbury, NJ), and the Boston Research Service Center, enhancing the Group’s ability to deliver end-to-end services across Research, Development, and Manufacturing in the U.S. This build-out further strengthens the Group’s global footprint and reinforces its commitment to serving clients closer to key innovation and commercial markets.
    • Chengdu, China: Construction began on a new microbial manufacturing facility, featuring a 15,000L fermenter and scalable capacity up to 60,000L. The site will utilize the recently launched EffiX™ microbial expression platform to deliver high-yield, consistent, and scalable production of biologics.
    • Hangzhou, China: The first commercial PPQ campaign was completed at the 15,000L line in MFG20 – Asia’s first 5,000L drug substance scale-out line using single-use bioreactors (SUBs). This achievement underscores the Group’s advanced capabilities in leveraging single-use systems for large-scale commercial manufacturing.
  • Asset Optimization 

During the Reporting Period, the Group executed two strategic transactions aimed at optimizing global operations and improving asset efficiency. The asset transfer of WuXi Vaccines’ facility in Dundalk, Ireland to MSD International GmbH, was completed in March 2025. In May 2025, the Group entered into a definitive agreement to divest its DP facility in Leverkusen, Germany to Terumo Corporation. The transaction enables the Group to reallocate resources toward scaling large-scale DP manufacturing capabilities in Singapore. The divestment supports greater operational agility, improved asset efficiency, and the continued expansion of diversified solutions for global clients. The transaction is expected to close in the fourth quarter of 2025.

  • Backlog

As of Jun 30, 2025, total backlog increased to US$20.34 billion, comprising US$11.35 billion service backlog and US$9.0 billion of potential milestone payments. Backlog within 3 years increased to US$4.21 billion from US$3.65 billion as of December 2024, enhancing near-term revenue visibility.

  • Quality

The Group remains steadfast in its commitment to quality, ensuring the protection of client and partner interests through a globally recognized quality management system. Since 2017, the Group has successfully completed 44 regulatory inspections by major national authorities — including 22 by the U.S. FDA and EU EMA — with no critical issues and zero data integrity findings. All five manufacturing facilities in Wuxi, China — including MFG1 and MFG5 (drug substance), and DP1, DP2, and DP5 (drug product) — also successfully passed U.S. FDA Pre-License Inspections (PLI). This achievement reinforces the Group’s consistent 100% PLI pass rate and highlights its uncompromising adherence to global quality standards.

  • Talents

As of June 30, 2025, the Group’s global workforce reached 12,552 employees, including 4,362 scientists, with a key talent retention rate of 98.8%. Effective global recruitment and talent development efforts have further strengthened our operational execution across regions, enabling timely project delivery and fueling ongoing innovation.

  • WBS (WuXi Biologics Business System)

Introduced in 2021 and implemented across all business units and functions, WBS continues to drive operational excellence by improving efficiency, enhancing quality, and reducing costs – delivering greater value to clients.

During the Reporting Period, the Group executed approximately 130 Kaizen projects and events, contributing to a 100-basis point improvement in gross profit margin. These initiatives also supported business growth, improved labor efficiency, lowered costs, and enhanced quality outcomes.

In parallel, ESG-focused Kaizen projects advanced the Group’s sustainability goals, achieving meaningful reductions in carbon emissions, water consumption, waste generation, and energy usage. The Group remains committed to deepening WBS adoption, fostering a culture of continuous improvement, and enhancing long-term value creation through innovation and talent development.

  • Sustainability 

Sustainability remains a cornerstone of the Group’s long-term strategy, closely integrated with its corporate vision and mission. During the Reporting Period, the Group achieved meaningful progress across key ESG pillars and received broad recognition from leading global rating agencies.

Notable accolades include inclusion in the Dow Jones Sustainability Indices, AAA ESG Ratings from MSCI, selection into MSCI ESG Indexes, and the EcoVadis Platinum Medal. The Group also earned the highest negligible-risk rating from Sustainalytics and was recognized as both an Industry and Regional ESG Top-Rated Company. Additional honors include placement on CDP’s Water Security and Supplier Engagement “A List”, as well as an A- score for CDP Climate Change, reflecting leadership in environmental transparency and actions.

Management Comment

Dr. Chris Chen, CEO of WuXi Biologics, stated, “In the first half of 2025, we achieved solid and profitable growth, delivering a 16.1% YoY increase in Group revenue and expanding operating margin while navigating the macroenvironment. M revenue grew 24.9% YoY, with 25 PPQs scheduled for 2025. 86 new integrated projects were added during the Reporting Period, a record first-half. Our unique CRDMO business model, together with the disciplined execution of our ‘Follow and Win the Molecule’ strategies, enabled us to capture new business opportunities, accelerate client pipelines, and deepen long-term partnerships.” 

Dr. Chen added, “Combining WBS with ongoing investments in advanced technologies and digital platforms, we are enhancing efficiency, accelerating execution, and driving innovation. We are also strengthening our global footprint and reinforcing our commitment to serving clients closer to centers of innovation and key commercial markets. We remain committed to the highest standards of compliance while enabling our clients and partners to bring innovative biologics to patients worldwide. Our strong first-half results boost our confidence in delivering accelerated growth and support a revenue target increase.”

Dr. Ge Li, Chairman of WuXi Biologics, concluded, “WuXi Biologics demonstrated resilience and delivered solid performance in the first half of 2025. Guided by our client-first philosophy and supported by our fully integrated open-access platform, we continue to advance global biopharmaceutical discovery, development, and manufacturing. Looking ahead, we remain committed to creating greater value for clients and better outcomes for patients, as we pursue our vision that ‘every biologic can be made’.”

Key Financial Ratios

(For the Six Months Ended June 30)

Key Financial Ratio

1H 2025

1H 2024

Change

Revenue (In RMB million)

9,953.2

8,574.2

16.1 %

Gross Profit (In RMB million)

4,252.9

3,350.0

27.0 %

Margin (%)

42.7 %

39.1 %

Net Profit (In RMB million)

2,756.6

1,780.3

54.8 %

Margin (%)

27.7 %

20.8 %

Net Profit Attributable to Owners of the
Company (In RMB million)

2,339.3

1,499.1

56.0 %

Margin (%)

23.5 %

17.5 %

Adjusted Net Profit (In RMB million)

2,840.0

2,544.8

11.6 %

Margin (%)

28.5 %

29.7 %

EBITDA (In RMB million)

4,221.8

2,805.9

50.5 %

Margin (%)

42.4 %

32.7 %

Adjusted EBITDA (In RMB million)

4,305.2

3,570.4

20.6 %

Margin (%)

43.3 %

41.6 %

Adjusted Basic EPS (In RMB)

0.59

0.55

7.3 %

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2025, WuXi Biologics is supporting 864 integrated client projects, including 24 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Forward-Looking Statements

This announcement may contain certain “forward-looking statements” that are not historical facts, but instead are predictions about future events based on our expectations as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our clients’ intellectual property. Our forward-looking statements in this announcement speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Non-IFRS Measures

To supplement the Group’s condensed consolidated financial statements which are presented in accordance with the IFRS, the Company has provided adjusted net profit, adjusted net profit margin, adjusted EBITDA, adjusted EBITDA margin and adjusted basic and diluted earnings per share as additional financial measures, which are not required by, or presented in accordance with, the IFRS.

The Company believes that the adjusted financial measures are useful for understanding and assessing underlying business performance and operating trends, and that the Company’s management and investors may benefit from referring to these adjusted financial measures in assessing the Group’s financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that the Group does not consider indicative of the performance of the Group’s core business. These non-IFRS financial measures, as the management of the Group believes, is widely accepted and adopted in the industry in which the Group is operating in. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. Shareholders of the Company and potential investors should not view the adjusted results on a stand-alone basis or as a substitute for results under IFRS. And these non-IFRS financial measures may not be comparable to similarly-titled measures represented by other companies.

Contacts

Media
PR@wuxibiologics.com 

Investors
IR@wuxibiologics.com

 

 

HT Materials Science Delivers Substantial Energy Savings for DKSH Malaysia

Installing Maxwell® led to a 13% reduction in chiller energy consumption and projected annual savings of 600,000 kWh

DUBLIN, Aug. 19, 2025 /PRNewswire/ — HT Materials Science (HTMS), a global leader in cooling technology, has successfully implemented its breakthrough heat-transfer fluid, Maxwell®, at a pharmaceutical cold storage facility operated by DKSH Malaysia. The installation resulted in significant energy savings, operational improvements and system performance—positioning the project as one of Southeast Asia’s most effective commercial HVAC retrofits to date.

Created by suspending sub-micron particles of aluminum oxide in a base fluid of water or glycol, Maxwell is a non-toxic, fully recyclable additive that enhances heat transfer in industrial HVAC systems. That improved heat transfer reduces energy consumption while increasing system capacity. For the DKSH Malaysia project, adding Maxwell led to a 13 percent reduction in the chiller’s energy consumption, for a projected annual savings of 600,000 kilowatt hours and a payback period of 2.1 years. This installation was procured and engineered by Tri Quantity Sdn Bhd, an energy management and audit company based in Malaysia.

Based on energy savings alone, the payback period for this project is projected at just over two years. It’s a welcome innovation for a facility with strict temperature and humidity needs and regulations, as installing Maxwell® requires no system downtime. In addition to energy savings, DKSH expects reduced wear and tear on the facility’s HVAC equipment, longer system lifespan and lower maintenance costs due to reduced scaling and improved fluid dynamics.

“This installation demonstrates that smart, science-driven HVAC technologies can deliver immediate cost savings and long-term sustainability benefits,” said Thomas Grizzetti, CEO of HTMS. “We’re proud to partner with forward-thinking companies like Tri Quantity and DKSH who are helping to set the standards for energy efficiency in large-scale commercial facilities.”

“This initiative not only strengthens our operational efficiency but also reaffirms DKSH’s commitment to sustainable, future-focused business practices,” said Joel Solomon, Head, Supply Chain Management, DKSH Malaysia & Brunei.

This project provides a compelling blueprint for how commercial facilities can unlock measurable energy gains through smart retrofits. The results are applicable across industries including logistics, education, retail and data centers. HTMS contracts include performance guarantees, with minimum savings thresholds and annual reconciliation.

“What makes this so compelling is the speed at which results materialized,” added Grizzetti. “Within weeks, we saw verified energy savings—demonstrating just how accessible and impactful these upgrades can be for building operators anywhere in the world.”

About DKSH

For 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services, following its purpose of enriching people’s lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 28,060 specialists, generating net sales of CHF 11.1 billion in 2024. www.dksh.com

About HT Materials Science

Based in Ireland, HTMS is dedicated to developing sustainable energy savings solutions aimed at improving the efficiency of HVAC systems in commercial and industrial sectors. HTMS was included this year in Fast Company’s list of Most Innovative Companies. The company’s flagship product, a heat-transfer fluid called Maxwell, is designed to enhance heat transfer and significantly reduce energy consumption, helping companies meet sustainability goals and combat climate change. https://htmaterialsscience.com/

About Tri Quantity

Based in Selangor, Tri Quantity provides energy management and audit services in Malaysia, Singapore and Asia. Tri Quantity is the exclusive distributor of Maxwell in the region. https://www.triquantity.com/